Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been
made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are …

Antibody-dependent cellular cytotoxicity (ADCC) is mediated through the engagement of the
Fc segment of antibodies with Fcγ receptors (FcγRs) on immune cells upon binding of tumor …

The engineering of therapeutic and clinical candidate monoclonal antibodies and Fc fusion
proteins is becoming more sophisticated at generating molecules that are better suited to the …

The direct or indirect targeting of antibody Fc receptors (FcRs) presents unique opportunities
and interesting challenges for the treatment of inflammatory diseases, cancer and infection …

The Fc region of the IgG antibody recruits immune leukocytes or serum complement
molecules, which in turn triggers the clearance of defective cells such as tumor cells or …

Antibody-dependent cell-mediated cytotoxicity, a key effector function for the clinical efficacy
of monoclonal antibodies, is mediated primarily through a set of closely related Fcγ …

The in vivo biological activities of IgG antibodies result from their bifunctional nature, in
which antigen recognition by the Fab is coupled to the effector and immunomodulatory …

Autoantibody immune complex (IC) activation of Fcγ receptors (FcγRs) is a common
pathogenic hallmark of multiple autoimmune diseases. Given that the IC structural features …

IgG isotypes can differentially bind to Fcγ receptors and complement, making the selection of
which isotype to pursue for development of a particular therapeutic antibody important in …

Therapeutic monoclonal antibodies and Fc-fusion proteins are successfully used in
treatment of various diseases mainly including cancer, immune disease, and viral infection …